Age-dependent association of KIBRA genetic variation and Alzheimer's disease risk

• Published in: Neurobiology of aging Vol. 30; no. 2; pp. 322 - 324
• Main Authors: Rodríguez-Rodríguez, Eloy, Infante, Jon, Llorca, Javier, Mateo, Ignacio, Sánchez-Quintana, Coro, García-Gorostiaga, Inés, Sánchez-Juan, Pascual, Berciano, José, Combarros, Onofre
• Format: Journal Article
• Language: English
• Published: London Elsevier Inc 01.02.2009; Elsevier
• Subjects: Aged; Aged, 80 and over; Aging - genetics; Alzheimer Disease - epidemiology; Alzheimer Disease - genetics; Alzheimer's disease; Biological and medical sciences; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases; Development. Senescence. Regeneration. Transplantation; Episodic memory; Female; Fundamental and applied biological sciences. Psychology; Genetic Predisposition to Disease - epidemiology; Genetic Predisposition to Disease - genetics; Genetic Variation - genetics; Humans; Incidence; Internal Medicine; Intracellular Signaling Peptides and Proteins; KIBRA; Male; Medical sciences; Middle Aged; Neurology; Phosphoproteins; Polymorphism; Polymorphism, Single Nucleotide - genetics; Proteins - genetics; Risk Assessment - methods; Risk Factors; Spain - epidemiology; Vertebrates: nervous system and sense organs; Spain; KIBRA; Alzheimer's disease; Episodic memory; Polymorphism; Nervous system diseases; Senescence; Alzheimer disease; Memory; Central nervous system disease; Degenerative disease; Age; Cerebral disorder
• ISSN: 0197-4580; 1558-1497; 1558-1497
• DOI: 10.1016/j.neurobiolaging.2007.07.003

An association between memory performance in healthy young, middle aged an elderly subjects and variability in the KIBRA gene (rs17070145) has been recently described. We analyzed this polymorphism in 391 sporadic Alzheimer's disease (AD) patients and 428 cognitively normal control subjects. The current study reveals that KIBRA (rs17070145) T allele (CT and TT genotypes) is associated with an increased risk (OR 2.89; p=0.03) for very-late-onset (after the age of 86 years) AD.